MedTrace Logo

Effect of holoBLG on Cat Allergic Patients

NCT05455749 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-12-18

No results posted yet for this study

Summary

The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid, zinc and polyphenols (holo-BLG) in patients with allergic rhinoconjunctivitis caused by cat (hair/dander) and the associated symptoms (symptom type and severity) during exposure to cat allergen in an Allergen Exposure Chamber (AEC).

Conditions

  • Allergy to Cats
  • Allergic Rhinoconjunctivitis

Interventions

DIETARY_SUPPLEMENT

holoBLG

holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)

Sponsors & Collaborators

  • Ecarf Institute GmbH

    collaborator OTHER

  • Bencard Allergie GmbH

    collaborator OTHER

  • Allergy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Karl-Christian Bergmann, Prof. Dr. med. · Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2022-03-15
Completion
2022-03-16

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455749 on ClinicalTrials.gov